Concept
Selective glucocorticoid receptor modulator
Personnes associées (23)
Maria del Carmen Sandi Perez
ACADEMIC POSITION:
Professor, Director of the Laboratory of Behavioral Genetics, Brain Mind Institute, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland.
EDUCATION:
BS MS Salamanca, Spain, 1984
PhD Cajal Institute, CSIC, and University Autonoma of Madrid, Spain, 1988
PROFESSIONAL EXPERIENCE:
Postdoc at INSERM, Bordeaux, France, and Cajal Institute Madrid, Spain, 1989-1990
Postdoc at the Open University, UK, 1991-1992, 1996
Research Associate, Cajal Institute, CSIC, Madrid, 1993-1995
Associate Professor Tenured, UNED University, Madrid, 1996-2003
Sabbatical Professor, University of Bern, Switzerland, 2002-2003
Assistant Professor Tenure-Track, EPFL, 2003-2007
Associate Professor Tenured, EPFL, 2007-2012
Full Professor, EPFL, 2012-
Director, Brain Mind Institute, EPFL, 2012-
PRINCIPAL BOARDS:
President, European Brain and Behavior Society (EBBS), 2009-2012
Editor-in-Chief Frontiers in Behavioral Neuroscience
Member of Scientific Advisory Panel, European College Neuropsychopharmacology (ECNP)
Member of the European Dana Alliance for the Brain (EDAB)
Associate Editor Frontiers in Neuroscience
Editorial Board Member Neurobiology of Learning and Memory
Editorial Board Member Journal of Psychiatry Research
Editorial Board Member Stress
Editorial Board Member Biology of Mood and Anxiety Disorders
Editorial Board Member Neuroscience and Biobehavioral Reviews
Johan Auwerx
Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Horst Vogel
Horst Vogel est né en 1948 à Würzburg, Allemagne. Après ses études en chimie, il obtient le diplôme de chimie en 1974 de l'Université de Würzburg.Il entreprend ensuite un travail de doctorat au Max-Planck Institut für Biophysikalische Chemie de Göttingen, et obtient en 1978 le grade de docteur ès sciences de l'Université de Göttingen. De 1978 à 1983 il effectue des recherches au Max-Planck Institut für Biologie à Tübingen et en 1984, il rejoint le Biocentre à Bâle où il travaille jusqu'en 1989, effectuant une année au Karolinska Institute à Stockholm. En 1989, Horst Vogel rejoint l'institut de chimie physique de l'EPFL où il dirige un groupe travaillant dans les domaines de la biophysique et de la bioélectronique.
Depuis le 1er octobre 1994 il est profeseur en chimie physique des polymères et membranes au Département de chimie de EPFL. Ses intérêts de recherche sont l'étude de la structure et de la dynamique de récepteurs membranaires et l'auto-assemblage des biomolécules aux interfaces pour développer de nouveaux biocapteurs dans le domaine de micro- et nanotechnologie. Il enseigne les sciences du vivant, la biophysique et biochimie, et des chapitres concernant la biotechnologie.
Dipl. in Chemistry1974-Univ. Würzburg, DE
Ph.D.-1978-MPI für Biophys. Chemie, Göttingen, DE
Pierre Vogel
Professional positions:
P. Vogel was born in Cully (Switzerland) Oct. 23, 1944. In 1969, he did his Ph.D Award under supervision of Prof. H. Prinzbach at the Institute of Organic Chemistry, University of Lausanne. After finishing his Ph.D in 1969, he did post-doctoral research at Yale University, New Haven, Connecticut, USA with Prof. Martin Saunders; research associate with Prof. J. A. Berson, K. A. Wiberg and P.v.R. Schleyer (Princeton Universtiy). From 1971 he worked as a Research chemist at Syntex S.A., in Mexico with Prof. P.Crabbé before he returned to the University of Lausanne in 1972. As of 1977 he became Professor of organic chemistry at the University of Lausanne. In 1991 he was Vice-Chairman of the Institute of organic Chemistry, University of Lausanne until 2001. Then he was Part-time grad.school teacher at the Universitites of Rouen and Caen from 1991 to 1993 and Part-time professor at Ecole Polytechnique de Palaiseau from 1993-2000. From 2000-2001 he was reviewer of the "Institut Universitaire de France" and as of 2001 Professor of organic chemistry at the EPFL.
Degrees and distincions
1969 Ph.D, University of Lausanne
1976 Swiss Chemical Society Award, Werner Medal
1973-now Member of the Swiss Chemical Society, of the American Chemical
Society and "Société Française de Chimie"
1984-1989 IOCD adviser
1988-1989 Associate Professor of Organic Chemistry at Ecole Normale
Supérieure, Paris
1989-2000 Member of the Swiss National Council of Research
1991-1992 Associate Professor of Organic Chemistry, University of Paris VI
1992 Pacific Coast Lecturer (USA)
1992-1993 Associate Professor at the Université de Montpellier, France
1993 Associate Professor, Université Paris Sud, Orsay
1993-1997 Swiss co-ordinator of the European COST D2 research program
1994 (spring) Associate Professor, ESPCI, Paris
1997 President of the european COST D2 management committee
1999 Coordinator of the european COSRD13
2001-now Member of the "Conseil Scientifique du Département des Sciences
Chimiques", CNRS
2002-2003 Novartis Lectureship
2004-2005 Boehringer INgelheim Distinguished Lecturer
Hilal Lashuel
2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies.
Georges Wagnières
Georges Wagnières a obtenu son diplôme (MSc) en physique à l'Université de Lausanne, Suisse, en 1986. Il a reçu son doctorat ès science (PhD) en physique (Optique Biomédicale) de l'Ecole Polytechnique Fédérale de Lausanne (EPFL) en 1992, et a effectué un travail de postdoctorat dans les "Wellman Laboratories of Photomedicine" (Harvard Medical School) situés à Boston, MA, USA, en 1993 et 1994. Il a aussi obtenu, en 2001, un "Master in management of technology" délivré par l'Ecole des Hautes Etudes Commerciales (HEC) de l'Université de Lausanne et l'EPFL. Depuis 1994, il gère un groupe de recherche de l'EPFL actif dans les domaines suivants: - Caractérisation et détection de lésions cancéreuses par spectroscopie et imagerie de fluorescence ainsi que par imagerie à fort grossissement. - Traitement du cancer ainsi que d'autres pathologies associées à des désordres immunologiques (maladie de Crohn, Colite ulcéreuse) ou vasculaires par thérapie photodynamique (PDT). - Développement préclinique et clinique de photosensibilisateurs, de marqueurs fluorescents et d'instruments optiques pour le photodiagnostic. - Traitement de diverses pathologies, y compris les maladies neuro-dégénératives (Parkinson, Alzheimer), par photobiomodulation. - Monitorage de la dose optique pour la PDT basée sur l'imagerie de fluorescence de photosensibilisateurs. - Induction de l'extravasation d'agent chimiothérapeutiques par PDT. - Mesure in vivo de la concentration d'oxygène dans des tissus biologiques par spectroscopie et imagerie optiques résolues en temps. - Monitorage d'un traitement au laser de la rétine par imagerie de reflectance. - Développement de distributeurs de lumière pour des applications biomédicales. - Dosimétrie de lumière / Radiométrie. - Spectroscopie et imagerie en optique biomédicale. Georges Wagnières est aussi co-fondateur et a présidé une société "spin-off" de l'EPFL: - Medlight SA, fondée en 1997, qui développe, produit et commercialise des distributeurs de lumière pour la thérapie photodynamique. Georges Wagnières est l'auteur et co-auteur de plus de 235 articles scientifiques dont 150 ont été publiés dans des revues internationales ayant un comité de relecture (review board). De plus, il est inventeur de 18 brevets. Finalement, il supervise ou a supervisé 12 doctorants et enseigne actuellement à l'EPFL l'optique biomédicale et la photomédecine au niveaux "master". Ces cours sont aussi donnés à l'Ecole doctorale (EDCH, EDSV) de l'EPFL. Finalement, il donne le cours intitulé "Physique Générale I" aux biologistes de première année inscrits à l'Ecole de Biologie de l'Université de Lausanne. PUBLICATIONS PRINCIPALES: SVP visiter: https://www.epfl.ch/labs/lifmet/wagnieres/publications/